FTB Advisors Inc. Boosts Position in Alexion Pharmaceuticals, Inc. (ALXN)

FTB Advisors Inc. boosted its holdings in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 8.1% in the first quarter, according to its most recent filing with the SEC. The institutional investor owned 3,690 shares of the biopharmaceutical company’s stock after buying an additional 275 shares during the period. FTB Advisors Inc.’s holdings in Alexion Pharmaceuticals were worth $499,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of ALXN. FMR LLC grew its position in shares of Alexion Pharmaceuticals by 25.1% during the fourth quarter. FMR LLC now owns 26,398,265 shares of the biopharmaceutical company’s stock valued at $2,570,135,000 after purchasing an additional 5,301,272 shares in the last quarter. Norges Bank purchased a new position in shares of Alexion Pharmaceuticals during the fourth quarter valued at about $388,934,000. Clearbridge Investments LLC grew its position in shares of Alexion Pharmaceuticals by 15.4% during the third quarter. Clearbridge Investments LLC now owns 5,178,157 shares of the biopharmaceutical company’s stock valued at $719,816,000 after purchasing an additional 691,390 shares in the last quarter. Swedbank grew its position in shares of Alexion Pharmaceuticals by 46.6% during the fourth quarter. Swedbank now owns 861,345 shares of the biopharmaceutical company’s stock valued at $83,731,000 after purchasing an additional 273,800 shares in the last quarter. Finally, Investec Asset Management LTD grew its position in shares of Alexion Pharmaceuticals by 16.7% during the first quarter. Investec Asset Management LTD now owns 1,673,504 shares of the biopharmaceutical company’s stock valued at $226,224,000 after purchasing an additional 240,014 shares in the last quarter. Institutional investors and hedge funds own 94.82% of the company’s stock.

NASDAQ ALXN traded down $1.25 during trading on Wednesday, hitting $127.55. The stock had a trading volume of 1,090,690 shares, compared to its average volume of 1,494,418. The company has a debt-to-equity ratio of 0.25, a current ratio of 3.87 and a quick ratio of 3.36. The company has a market cap of $28.68 billion, a P/E ratio of 17.99, a PEG ratio of 1.03 and a beta of 1.53. Alexion Pharmaceuticals, Inc. has a one year low of $92.56 and a one year high of $141.86.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported $2.39 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.99 by $0.40. Alexion Pharmaceuticals had a net margin of 9.59% and a return on equity of 19.53%. The business had revenue of $1.14 billion during the quarter, compared to the consensus estimate of $1.13 billion. During the same quarter last year, the firm earned $1.68 earnings per share. The firm’s quarterly revenue was up 22.5% compared to the same quarter last year. As a group, equities research analysts expect that Alexion Pharmaceuticals, Inc. will post 8.6 EPS for the current year.

A number of brokerages have recently weighed in on ALXN. Raymond James began coverage on Alexion Pharmaceuticals in a research report on Wednesday, April 10th. They set an “outperform” rating and a $161.00 price objective for the company. BidaskClub upgraded Alexion Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, March 1st. Royal Bank of Canada restated an “outperform” rating and set a $186.00 price objective (up previously from $165.00) on shares of Alexion Pharmaceuticals in a research report on Wednesday, March 27th. Cowen restated a “buy” rating and set a $165.00 price objective on shares of Alexion Pharmaceuticals in a research report on Wednesday, March 13th. Finally, TheStreet upgraded Alexion Pharmaceuticals from a “c” rating to a “b” rating in a research report on Thursday, April 25th. Five research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. Alexion Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $163.06.

ILLEGAL ACTIVITY NOTICE: This article was originally published by Sundance Herald and is the property of of Sundance Herald. If you are reading this article on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright law. The legal version of this article can be viewed at https://sundanceherald.com/2019/05/22/ftb-advisors-inc-buys-275-shares-of-alexion-pharmaceuticals-inc-alxn.html.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.

Featured Story: Initial Public Offering (IPO)

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply